Jump to contentJump to search


  • Kutzsche J, Guzman GA, Willuweit A, Kletke O, Wollert E, Gering I, Jürgens D, Breitkreutz J, Stark H, Beck-Sickinge AG, Klöcker N, Hidalgo P, Willbold D. 
    An orally available N-type calcium channel inhibitor for the treatment of neuropathic pain.  
    Br J Pharmacol. , (2023) 
  • Kutzsche J, Schemmert S, Bujnicki T, Zafiu C, Halbgebauer S, Kraemer-Schulien V, Pils M, Blömeke L, Post J, Kulawik A, Jürgens D, Rossberg WM, Hümpel M, Bannach O, Otto M, Araujo JA, Willuweit A, Willbold D. 
    Oral treatment with the all-d-peptide RD2 enhances cognition in aged beagle dogs - A model of sporadic Alzheimer's disease  
    Heliyon 29;9(8):e18443, (2023) 
  • Wintz K, Post J, Langen K-J, Willbold D, Willuweit A, Kutzsche J 
    Oral Treatment with d-RD2RD2 Impedes Early Disease Mechanisms in SOD1*G93A Transgenic Mice but Does Not Prolong Survival  
    Biomedicines 11(4), 995, (2023) 
  • Kass B, Schemmert S, Zafiu C, Pils M, Bannach O, Kutzsche J, Bujnicki T, Willbold D. 
    Aβ oligomer concentration in mouse and human brain and its drug-induced reduction ex vivo. 
    Cell Rep Med. 3(5):100630, (2022) 
  • Sevenich M, Honold D, Willuweit A, Kutzsche J, Mohrlüder J, Willbold D. 
    Development of an α-synuclein fibril and oligomer specific tracer for diagnosis of Parkinson's disease, dementia with Lewy bodies and multiple system atrophy.  
    Neurochem Int. 161, 105422 (2022) 
  • Bocharov, E. V., L. Gremer, A. S. Urban, I. S. Okhrimenko, P. E. Volynsky, K. D. Nadezhdin, O. V. Bocharova, D. A. Kornilov, Y. A. Zagryadskaya, A. V. Kamynina, P. K. Kuzmichev, J. Kutzsche, N. Bolakhrif, A. Müller-Schiffmann, N. A. Dencher, A. S. Arseniev, R. G. Efremov, V. I. Gordeliy and D. Willbold 
    All-d-Enantiomeric Peptide D3 Designed for Alzheimer’s Disease Treatment Dynamically Interacts with Membrane-Bound Amyloid-β Precursors. 
    Journal of Medicinal Chemistry , (2021) 
  • Camargo LC, Honold D, Bauer R, Shah NJ, Langen KJ, Willbold D, Kutzsche J, Willuweit A, Schemmert S. 
    Sex-Related Motor Deficits in the Tau-P301L Mouse Model 
    Biomedicines 9(9):1160, (2021) 
  • Camargo LC, Schöneck M, Sangarapillai N, Honold D, Shah NJ, Langen KJ, Willbold D, Kutzsche J, Schemmert S, Willuweit A 
    PEAβ Triggers Cognitive Decline and Amyloid Burden in a Novel Mouse Model of Alzheimer's Disease 
    Int J Mol Sci. 22(13):706, (2021) 
  • Post J, Kogel V, Schaffrath A, Lohmann P, Shah NJ, Langen K-J, Willbold D, Willuweit A, Kutzsche J 
    A Novel Anti-Inflammatory d-Peptide Inhibits Disease Phenotype Progression in an ALS Mouse Model. 
    Molecules 26(6):1590, (2021) 
  • Post J, Schaffrath A, Gering I, Hartwig S, Lehr S, Shah NJ, Langen KJ, Willbold D, Kutzsche J, Willuweit A. 
    Oral Treatment with RD2RD2 Impedes Development of Motoric Phenotype and Delays Symptom Onset in SOD1 G93A Transgenic Mice  
    Int J Mol Sci . 22(13):7066, (2021) 
  • Elfgen A, Santiago-Schübel B, Hupert M, Schemmert S, Schartmann E, Tusche M, Gering I, Zafiu C, Kutzsche J. 
    Oral absorption enhancement of the amyloid-β oligomer eliminating compound RD2 by conjugation with folic acid  
    Eur J Pharm Sci. , (2020) 
  • Kutzsche J, Jürgens D, Willuweit A, Adermann K, Fuchs C, Simons S, Windisch M, Hümpel M, Rossberg W, Wolzt M, Willbold D. 
    Safety and Pharmacokinetics of the Orally Available Antiprionic Compound PRI-002: A Single and Multiple Ascending Dose Phase I Study 
    Alzheimers Dement (N Y) , 20;6(1):e12001 (2020) 
  • Dieter Willbold and Janine Kutzsche 
    Do We Need Anti-Prion Compounds to Treat Alzheimer’s Disease? 
    Molecules 24, 2237 (2019) 
  • Elfgen A, Hupert M, Bochinsky K, Tusche M, González de San Román Martin E, Gering I, Sacchi S, Pollegioni L, Huesgen PF, Hartmann R, Santiago-Schübel B, Kutzsche J, Willbold D. 
    Metabolic resistance of the D-peptide RD2 developed for direct elimination of amyloid-β oligomers 
    Sci Rep 9(1), 5715 (2019) 
  • Schemmert S, Schartmann E, Honold D, Zafiu C, Ziehm T, Langen KJ, Shah NJ, Kutzsche J, Willuweit A, Willbold D. 
    Deceleration of the neurodegenerative phenotype in pyroglutamate-Aβ accumulating transgenic mice by oral treatment with the Aβ oligomer eliminating compound RD2. 
    Neurobiol Dis. 124, 36-45 (2019) 
  • Schemmert S, Schartmann E, Zafiu C, Kass B, Hartwig S, Lehr S, Bannach O, Langen KJ, Shah NJ, Kutzsche J, Willuweit A, Willbold D. 
    Aβ Oligomer Elimination Restores Cognition in Transgenic Alzheimer's Mice with Full-blown Pathology. 
    Mol Neurobiol. 56(3):, 2211-2223 (2019) 
  • Zhang T, Gering I, Kutzsche J, Nagel-Steger L, Willbold D. 
    Toward the Mode of Action of the Clinical Stage All-d-Enantiomeric Peptide RD2 on Aβ42 Aggregation. 
    ACS Chem Neurosci. 10(12), 4800-4809. (2019) 
  • Cavini IA, Munte CE, Erlach MB, van Groen T, Kadish I, Zhang T, Ziehm T, Nagel-Steger L, Kutzsche J, Kremer W, Willbold D, Kalbitzer HR. 
    Inhibition of amyloid Aβ aggregation by high pressures or specific d-enantiomeric peptides. 
    Chem Commun (Camb). 54(26), 3294-3297 (2018) 
  • Dunkelmann T, Teichmann K, Ziehm T, Schemmert S, Frenzel D, Tusche M, Dammers C, Jürgens D, Langen KJ, Demuth HU, Shah NJ, Kutzsche J, Willuweit A, Willbold D 
    Aβ oligomer eliminating compounds interfere successfully with pEAβ (3–42) induced motor neurodegenerative phenotype in transgenic mice 
    Neuropeptides 67, 27-35 (2018) 
  • Dunkelmann T, Schemmert S, Honold D, Teichmann K, Butzküven E, Demuth HU, Shah NJ, Langen KJ, Kutzsche J, Willbold D, Willuweit A. 
    Comprehensive Characterization of the Pyroglutamate Amyloid-β Induced Motor Neurodegenerative Phenotype of TBA2.1 Mice. 
    J Alzheimers Dis. 63(1), 115-130 (2018) 
  • Schartmann E, Schemmert S, Niemietz N, Honold D, Ziehm T, Tusche M, Elfgen A, Gering I, Brener O, Shah NJ, Langen KJ, Kutzsche J, Willbold D, Willuweit A. 
    In Vitro Potency and Preclinical Pharmacokinetic Comparison of All-D-Enantiomeric Peptides Developed for the Treatment of Alzheimer's Disease. 
    J Alzheimers Dis 64(3), 859-873 (2018) 
  • Elfgen A, Santiago-Schübel B, Gremer L, Kutzsche J, Willbold, D 
    Surprisingly high stability of the Aβ oligomer eliminating all-D-enantiomeric peptide D3 in media simulating the route of orally administered drugs 
    European Journal of Pharmaceutical Sciences 107, 203-207 (2017) 
  • Hupert M, Elfgen A, Schartmann E, Schemmert S, Buscher B, Kutzsche J, Willbold D, Santiago-Schübel B 
    Development and Validation of an UHPLC-ESI-QTOF-MS method for quantification of the highly hydrophilic amyloid-β oligomer eliminating all-D-enantiomeric peptide RD2 in mouse plasma 
    Journal of Chromatography B 1073, 123-129 (2017) 
  • Klein AN, Ziehm T, van Groen T, Kadish I, Elfgen A, Tusche M, Thomaier M, Reiss K, Brener O, Gremer L, Kutzsche J, Willbold D 
    Optimization of D-peptides for Aβ monomer binding specificity enhances their potential to eliminate toxic Aβ oligomers 
    ACS Chem Neurosci 8, 1889-1900 (2017) 
  • Kutzsche J, Schemmert S, Tusche M, Neddens J, Rabl R, Jürgens D, Brener O, Willuweit A, Hutter-Paier B, Willbold D. 
    Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer's Disease. 
    Molecules 22(10), (2017) 
  • Schartmann E, Schemmert S, Ziehm T, Leithold LHE, Jiang N, Tusche M, Shah NJ, Langen KJ, Kutzsche J, Willbold D, Willuweit A. 
    Comparison of blood-brain barrier penetration efficiencies between linear and cyclic all-d-enantiomeric peptides developed for the treatment of Alzheimer's disease. 
    Eur J Pharm Sci. 17, 0928-0987 (2017) 
  • van Groen T, Schemmert S, Brener O, Gremer L, Ziehm T, Tusche M, Nagel-Steger L, Kadish I, Schartmann E, Elfgen A, Jürgens D, Willuweit A, Kutzsche J, Willbold D. 
    The Aβ oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology. 
    Sci Rep. 7, 16275 (2017) 
  • Klein AN, Ziehm T, Tusche M, Buitenhuis J, Bartnik D, Boeddrich A, Wiglenda T, Wanker E, Funke SA, Brener O, Gremer L, Kutzsche J, Willbold D. 
    Optimization of the All-D Peptide D3 for Aβ Oligomer Elimination. 
    PLoS One 11(4), (2016) 
    Erratum in: PLoS One. 2016;11(7):e0158960. http://dx.doi.org/10.1371/journal.pone.0158960 
  • Leithold LH, Jiang N, Post J, Niemietz N, Schartmann E, Ziehm T, Kutzsche J, Shah NJ, Breitkreutz J, Langen KJ, Willuweit A, Willbold D.  
    Pharmacokinetic properties of tandem D-peptides designed for treatment of Alzheimer's disease 
    Eur. J. Pharm. Sci. 89, 31-38 (2016) 
  • Leithold LH, Jiang N, Post J, Ziehm T, Schartmann E, Kutzsche J, Shah NJ, Breitkreutz J, Langen KJ, Willuweit A, Willbold D. 
    Pharmacokinetic Properties of a Novel D-Peptide Developed to be Therapeutically Active Against Toxic β-Amyloid Oligomers 
    Pharm Res. 33, 328-336 (2016) 
  • Rudolph S, Klein AN, Tusche M, Schlosser C, Elfgen A, Brener O, Teunissen C,Gremer L, Funke SA, Kutzsche J, Willbold D. 
    Correction: Competitive Mirror Image Phage Display Derived Peptide Modulates Amyloid Beta Aggregation and Toxicity 
    PLoS One 11(7), (2016) 
  • Rudolph S, Klein AN, Tusche M, Schlosser C, Elfgen A, Brener O, Teunissen C, Gremer L, Funke SA, Kutzsche J, Willbold D.  
    Competitive Mirror Image Phage Display Derived Peptide Modulates Amyloid Beta Aggregation and Toxicity. 
    PLoS One 11(2):e0147470., (2016) 
  • Ziehm T, Brener O, van Groen T, Kadish I, Frenzel D, Tusche M, Kutzsche J, Reiß K, Gremer L, Nagel-Steger L, Willbold D. 
    Increase of Positive Net Charge and Conformational Rigidity Enhances the Efficacy of d-Enantiomeric Peptides Designed to Eliminate Cytotoxic Aβ Species. 
    ACS Chem Neurosci. 7 (8), 1088–1096 (2016) 
  • Brener O, Dunkelmann T, Gremer L, van Groen T, Mirecka EA, Kadish I, Willuweit A, Kutzsche J, Jürgens D, Rudolph S, Tusche M, Bongen P, Pietruszka J, Oesterhelt F, Langen K-J, Demuth H-U, Janssen A, Hoyer W, Funke SA, Nagel-Steger L, Willbold D 
    QIAD assay for quantitating a compound's efficacy in elimination of toxic Aβ oligomers. 
    Sci Rep 5, 13222 (2015) 
  • Jiang N, Leithold LH, Post J, Ziehm T, Mauler J, Gremer L, Cremer M, Schartmann E, Shah NJ, Kutzsche J, Langen KJ, Breitkreutz J, Willbold D, Willuweit A 
    Preclinical Pharmacokinetic Studies of the Tritium Labelled D-Enantiomeric Peptide D3 Developed for the Treatment of Alzheimer´s Disease 
    PLoS One 10, e0128553 (2015) 
  • Pattky M, Nicolardi S, Santiago-Schübel B, Sydes D, van der Burgt YE, Klein AN, Jiang N, Mohrlüder J, Hänel K, Kutzsche J, Funke SA, Willbold D, Willbold S, Huhn C 
    Structure characterization of unexpected covalent O-sulfonation and ion-pairing on an extremely hydrophilic peptide with CE-MS and FT-ICR-MS. 
    Anal. Bioanal. Chem. 407, 6637-6655 (2015) 
Responsible for the content: